Michael D Parkes1, Philip F Halloran, Luis G Hidalgo. 1. 1 Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada. 2 Department of Medicine, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, AB, Canada. 3 Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada.
Abstract
BACKGROUND: Natural killer (NK) cells localize in the microcirculation in antibody-mediated rejection (AMR) and have been postulated to be activated by donor-specific anti-HLA antibodies triggering their CD16a Fc receptors. However, direct evidence for NK cell CD16a triggering in AMR is lacking. We hypothesized that CD16a-inducible NK cell-selective transcripts would be expressed in human AMR biopsies and would offer evidence for CD16a triggering. METHODS: We stimulated human NK cells through CD16a in vitro, characterized CD16a-inducible transcripts, and studied their expression in human kidney transplant biopsies with AMR and in an extended human cell panel to determine their selectivity. RESULTS: In NK cells, CD16a stimulation induced increased expression of 276 transcripts (FC > 2x, false discovery rate < 0.05), including IFNG, TNF, CSF2, chemokines, such as CCL3, CCL4, and XCL1, and modulators of NK cell effector functions (TNFRSF9, CRTAM, CD160). Examination in an extended human cell panel revealed that CD160 and XCL1 were likely to be selective for NK cells in AMR. In biopsies, 8 of the top 30 CD16a-inducible transcripts were highly associated with AMR (P < 5 × 10): CCL4, CD160, CCL3, XCL1, CRTAM, FCRL3, STARD4, TNFRSF9. Other NK cell transcripts (eg, GNLY) were increased in AMR but not CD16a-inducible, their presence in AMR probably reflecting NK cell localization. CONCLUSIONS: The association of CD16a-inducible NK cell-selective transcripts CD160 and XCL1 with biopsies with AMR provides evidence for NK cell CD16a activation in AMR. This raises the possibility of other CD16a-triggered effects that are not necessarily transcriptional, including NK localization and cytotoxicity.
BACKGROUND: Natural killer (NK) cells localize in the microcirculation in antibody-mediated rejection (AMR) and have been postulated to be activated by donor-specific anti-HLA antibodies triggering their CD16a Fc receptors. However, direct evidence for NK cell CD16a triggering in AMR is lacking. We hypothesized that CD16a-inducible NK cell-selective transcripts would be expressed in human AMR biopsies and would offer evidence for CD16a triggering. METHODS: We stimulated human NK cells through CD16a in vitro, characterized CD16a-inducible transcripts, and studied their expression in human kidney transplant biopsies with AMR and in an extended human cell panel to determine their selectivity. RESULTS: In NK cells, CD16a stimulation induced increased expression of 276 transcripts (FC > 2x, false discovery rate < 0.05), including IFNG, TNF, CSF2, chemokines, such as CCL3, CCL4, and XCL1, and modulators of NK cell effector functions (TNFRSF9, CRTAM, CD160). Examination in an extended human cell panel revealed that CD160 and XCL1 were likely to be selective for NK cells in AMR. In biopsies, 8 of the top 30 CD16a-inducible transcripts were highly associated with AMR (P < 5 × 10): CCL4, CD160, CCL3, XCL1, CRTAM, FCRL3, STARD4, TNFRSF9. Other NK cell transcripts (eg, GNLY) were increased in AMR but not CD16a-inducible, their presence in AMR probably reflecting NK cell localization. CONCLUSIONS: The association of CD16a-inducible NK cell-selective transcripts CD160 and XCL1 with biopsies with AMR provides evidence for NK cell CD16a activation in AMR. This raises the possibility of other CD16a-triggered effects that are not necessarily transcriptional, including NK localization and cytotoxicity.
Authors: T Hirohashi; C M Chase; P Della Pelle; D Sebastian; A Alessandrini; J C Madsen; P S Russell; R B Colvin Journal: Am J Transplant Date: 2011-11-09 Impact factor: 8.086
Authors: P F Halloran; A B Pereira; J Chang; A Matas; M Picton; D De Freitas; J Bromberg; D Serón; J Sellarés; G Einecke; J Reeve Journal: Am J Transplant Date: 2013-10-03 Impact factor: 8.086
Authors: T Kondo; K Morita; Y Watarai; M B Auerbach; D D Taub; A C Novick; H Toma; R L Fairchild Journal: Transplantation Date: 2000-03-15 Impact factor: 4.939
Authors: C Lefaucheur; D Nochy; G S Hill; C Suberbielle-Boissel; C Antoine; D Charron; D Glotz Journal: Am J Transplant Date: 2007-04 Impact factor: 8.086
Authors: Xuedong Wei; Nicole M Valenzuela; Maura Rossetti; Rebecca A Sosa; Jessica Nevarez-Mejia; Gregory A Fishbein; Arend Mulder; Jayeeta Dhar; Karen S Keslar; William M Baldwin; Robert L Fairchild; Jianquan Hou; Elaine F Reed Journal: Am J Transplant Date: 2020-05-22 Impact factor: 8.086
Authors: Takafumi Yagisawa; Toshiaki Tanaka; Satoshi Miyairi; Kazunari Tanabe; Nina Dvorina; Wayne M Yokoyama; Anna Valujskikh; William M Baldwin; Robert L Fairchild Journal: Kidney Int Date: 2018-11-29 Impact factor: 10.612